双功能化合物靶向降解免疫检查点蛋白PD-L1  

Bifunctional Compound for Targeted Degradation of the Immune Checkpoint Protein PD-L1

作　　者：陈从丽 师怀怀 郝芮 房丽晶[2] 徐华栋[1] Chen Congli;Shi Huaihuai;Hao Rui;Fang Lijing;Xu Huadong(School of Pharmacy,Changzhou University,Changzhou 213164;Institute of Biomedicine and Biotechnology,Shenzhen Institute of Advanced Technology,Chinese Academy of Sciences,Shenzhen 518055)

机构地区：[1]常州大学药学院,常州213164 [2]中国科学院深圳先进技术研究院生物医药与生物技术研究所,深圳518055

出　　处：《化学学报》2024年第6期613-620,共8页Acta Chimica Sinica

基　　金：国家自然科学基金(No.22177015);江苏省自然科学基金(No.BK20211334);深圳市科委项目(Nos.JCYJ20220818101404010,JCYJ20220818100412028)资助。

摘　　要：本研究利用整合素促进的靶蛋白溶酶体降解策略,设计合成了识别整合素受体αvβ3的小分子Gua-Azide以替代c(RGDyK)环肽,通过连接子使其与PD-L1抑制剂BMS-8相连,形成双功能小分子降解剂.该降解剂能够通过内吞-溶酶体途径靶向降解细胞膜上的PD-L1靶标蛋白,为开发癌症免疫治疗相关小分子药物开辟了新途径.Programmed death ligand 1(PD-L1)is a protein overexpressed in numerous tumor cells as an essential immune checkpoint that can facilitate immune escape of tumor cells through binding to PD-1 on T cells.Compared to antibody drugs targeting PD-L1 or PD-1,which are limited in clinical application due to their immunogenicity,high cost and low oral bioa-vailability,small molecule inhibitors exhibit better tissue and tumor penetration ability,as well as higher bioavailability.However,traditional small molecule inhibitors often face drug resistance issues and are difficult to inhibit protein-protein interactions.Targeted protein degradation(TPD)technologies achieve a more comprehensive suppression of protein activity by degrading the target protein,thereby eliminating its functions entirely.The strategy not only reduces the drug resistance but also enhances the therapeutic efficacy.In the previous study,we have developed the integrin-facilitated lysosome degra-dation(IFLD)strategy to degrade extracellular and cell membrane proteins by using bifunctional compounds containing a target protein-binding domain,and a cyclic RGD peptide as the integrin-binding domain,connected via a linker.The cyclic RGD peptide,which incorporates the sequence arginine-glycine-aspartic acid(RGD),has been extensively employed for the development of targeted drug delivery systems.It specifically recognizes the integrinαvβ3,which is overexpressed in a varie-ty of tumor cells and plays a significant role in tumor-targeted drug delivery.Considering the instability of the RGD peptide,we designed and synthesized a small molecule compound,Gua-Azide,in this study to mimick the RGD(Arg-Gly-Asp)pep-tide to bind withαvβ3 integrin.Subsequently,we constructed a new IFLD degrader targeting PD-L1,BMS-Gua,through the conjugation of Gua-Azide with BMS-8,a small molecule with high binding affinity to PD-L1,by using click chemistry.The western blotting and immunofluorescence analysis verified that BMS-Gua,a bifunctional molecule degrader,could effec-tively ind

关 键 词：蛋白质靶向降解 IFLD策略 双功能降解剂 PD-L1 肿瘤免疫治疗 

分 类 号：R730.51[医药卫生—肿瘤]